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Bladder cancer is the sixth most commonly diagnosed cancer in the European
Union. Here, we evaluate the performance of a novel, commercially available
enzyme-linked immunosorbent assay utilising MCM5 antibodies (ADXBLADDER;
Arquer Diagnostics Ltd, Sunderland, UK) for the detection of bladder cancer, in a
blinded, prospective study of 856 patients, across seven centres, presenting with
haematuria. The results were compared with the patients’ clinical data and ﬁnal
diagnosis as deﬁned by the results of the imaging and cystoscopy, with a prevalence
of bladder cancer of 8.6%. ADXBLADDER detected bladder tumours in 54/74 cancers,
giving overall sensitivity of 73.0% and an overall negative predictive value (NPV) of
96.4%. Sensitivity and NPV of ADXBLADDER were highest in muscle-invasive
bladder cancer, both at 100%, and on analysis of non-pTa (pT1 and above) tumours,
the sensitivity for detection was 97% with an NPV of 99.8%. A subset of 173 patients
had matching cytology data; of these patients, 18 were positive for bladder cancer.
ADXBLADDER detected 16/18 of these cancers, whilst cytology was positive in only
four of 18, providing evidence that ADXBLADDER may be a more sensitive test for
bladder cancer than standard urine cytology.
Patient summary: We conducted a large clinical study of a novel, simple urine test
(ADXBLADDER), which measures a protein (MCM5) in urine and can be used to
detect bladder cancer in patients. We recruited 856 patients and demonstrated that
the new urine test can detect bladder cancer with a high degree of accuracy,
performing better than the most commonly used urine test—urine cytology. In
conclusion, this novel ADXBLADDER urine test can be used to help detect bladder
cancers and it can replace the current, standard urine test.
© 2019 The Authors. Published by Elsevier B.V. on behalf of European Association of
Urology. This is an open access article under the CC BY-NC-ND license (http://creati-
vecommons.org/licenses/by-nc-nd/4.0/).. Newcastle University and Sunderland Royal Hospital, Northern Institute for
Gorman Building, Framlington Place, Newcastle University, Newcastle upon
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cancer in the European Union (EU), with up to 70% of
bladder cancers recurring within the 1st year [1]. The
prevalence of this condition, and the nature of its
management and follow-up make it one of the most
expensive cancers, costing the EU s4.9 billion in 2012 and
representing 3% of all cancer costs in the EU [2]. Patients
with a primary, single, small TaG1 tumour have a very low
chance of progression (<1%), whilst the risk of progression
is much higher in patients with stage T1 disease, ranging
from 8% to 34%, depending on the depth of invasion of the
lamina propria [3,4]. Urine cytology is often used as an aid to
cystoscopy in the diagnosis of bladder cancer; however,
given the low sensitivity of cytology for low-grade tumours
(16%) [3], a negative cytology result is not indicative of the
absence of a tumour. Additionally, cytological interpretation
is user dependent, with evaluation hampered by low
cellular yields, urinary tract infections, and stones, under-
lining the current importance of the use of diagnostic
imaging in conjunction with cystoscopy [5].
MCM5 is an established biomarker in bladder cancer,
with detection of MCM5 in the urine of patients with
bladder cancer demonstrating excellent sensitivity as well
as a very high negative predictive value (NPV) [6,7];
however, earlier research methods were complicated and
not suitable for clinical use. Here, we evaluate for the first
time the performance of a novel, commercially available
enzyme-linked immunosorbent assay (ELISA) utilising
MCM5 antibodies, (ADXBLADDER; Arquer Diagnostics Ltd,
Sunderland, UK) for the detection of bladder cancer, in a
blinded, prospective study of patients presenting with
haematuria. MCM5 is a protein marker of replicating cells or
cells that have the capability to replicate. Fully differentiat-
ed cells lining the bladder, in contact with the urine, do not
contain MCM5, so MCM5 is not detectable in urine from a
healthy bladder. However, bladder cancer cells are capable
of undergoing cell division and therefore contain MCM5.
When a tumour is present within the bladder, these cells are
shed into the urine stream, resulting in a positive MCM5
ELISA test [6].
Between September 2016 and November 2017, eligible
patients presenting with visible or nonvisible haematuria
were recruited at urology clinics across seven UK study
centres. The patients had no previous diagnosis of bladder,
prostate, or renal cancer. Ethical approval was received from
the Office for Research Ethics Committee Northern Ireland
(15/NI/0258), and informed consent was obtained from all
patients prior to the collection of urine samples. A sample
size estimate calculation was carried out to determine the
performance of ADXBLADDER, based upon the data
obtained from feasibility studies and previously published
studies [6]. Based upon 80% power, with a 95% confidence
level, and assuming a prevalence of 7–10%, a total estimated
sample size of 731–1043 patients was required. Patients
with known calculi or active prostatitis were excluded from
the study (previous studies have shown that these
conditions may result in false positive MCM5 results due
to damage to the epithelium exposing normal expressing
MCM5 cells to the urine [6]). Patients with acute or chronicPlease cite this article in press as: Dudderidge T, et al. A Novel, n
Sediment of Patients Presenting with Haematuria—A Prospective M
Oncol (2019), https://doi.org/10.1016/j.euo.2019.06.006urinary tract infection and/or active haematuria (visible and
nonvisible) were eligible and therefore included in the
study. All patients underwent upper urinary tract imaging
(either ultrasound or computed tomography) and flexible
cystoscopy. A single, full-void urine sample was collected
from patients prior to cystoscopy and processed within 4 h
of collection. All urine samples >10 ml were included. Urine
sediment was collected by centrifugation and was resus-
pended in ADXBLADDER lysis buffer. Lysates were incubat-
ed for 30 min at room temperature to allow complete lysis
before being stored at 20 C or below, prior to testing with
ADXBLADDER as per the manufacturer’s instructions. The
results of the ADXBLADDER test were then compared with
the clinical data and the final diagnosis as defined by the
results of the imaging and cystoscopy.
The demographics of enrolled patients are summarised
in Supplementary Table 1. In total, 856 eligible patients
were enrolled with a median age of 64 yr (interquartile [IQ]
range 54–73 yr), of whom 74 were found to have a bladder
tumour (8.6%). Of the patients with bladder tumours, the
majority were males (74.3%) with a median age of 75 yr (IQ
range 66–80 yr).
ADXBLADDER demonstrated very high sensitivity of
97.0% (95% confidence interval [CI] 84.0–100%) and an NPV
of 99.8% (95% CI 98.7–100%) for the detection of bladder
tumours of stage pT1 and above. For muscle-invasive
bladder cancer, both sensitivity and NPV were 100% (16/16
tumours). In total, ADXBLADDER detected 54/74 cancers,
giving overall sensitivity of 73.0% (95% CI 61.40–82.60%), an
overall NPV of 96.4% (95% CI 94.50–97.80%), and an overall
specificity of 68.4% (95% CI 65.00–71.70%), with an area
under the receiver operator characteristic (ROC) curve
of 0.75 (95% CI 0.69–0.81; Supplementary Fig. 2A). Of the
20/74 tumours undetected by ADXBLADDER, 19/20 were
pTa tumours and 14/20 were found to have low-grade
disease. Reassuringly, in high-grade non-muscle-invasive
disease, sensitivity was high at 86% (95% CI 72–95%) with an
NPV of 99.8% (95% CI 97.6–99.6%; Fig. 1A–C).
A subset of 173 patients had available cytology data; of
these patients, 18 were positive for bladder cancer.
ADXBLADDER detected 16/18 of these cancers, whilst
cytology was positive in only four of these 18 cancers, with
six of these 18 having atypical/equivocal results, suggesting
that ADXBLADDER may be a more sensitive test for
bladder cancer than standard urine cytology (Fig. 1D and
Supplementary Fig. 2B). Patients recruited to the study
included those with both visible and nonvisible haematuria.
The performance of ADXBLADDER was consistent between
both types of haematuria (Fig. 2B) and with the overall
population, with no significant difference between the
areas under the ROC curves (Fig. 2C). This suggests a role for
ADXBLADDER in both visible and nonvisible haematuria.
Similarly, there were no significant differences in the
performance of ADXBLADDER, as assessed by the area
under the ROC curve, due to age (<75 vs 75 yr) or gender
(Fig. 2C).
An ideal diagnostic test for bladder cancer should be easy
to perform, with results promptly available to the clinic,
providing additional information to better manage theon-invasive Test Enabling Bladder Cancer Detection in Urine
ulticentre Performance Evaluation of ADXBLADDER. Eur Urol
Fig. 1 – (A) A 2 T 2 table of ADXBLADDER performance. (B) Sensitivity of ADXBLADDER associated with tumour stage. (C) Sensitivity and predictive
values of ADXBLADDER in patients by grade and stage. (D) ADXBLADDER comparisons with cytology. CI = confidence interval; MIBC = muscle-invasive
bladder cancer; NMIBC = non-muscle-invasive bladder cancer.
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non-invasive test should not be influenced by benign
conditions. In the past, urine-based biomarker tests for
bladder cancer have not gained widespread acceptance due
to their failure to meet or effectively demonstrate suchPlease cite this article in press as: Dudderidge T, et al. A Novel, n
Sediment of Patients Presenting with Haematuria—A Prospective M
Oncol (2019), https://doi.org/10.1016/j.euo.2019.06.006criteria [8]. The results presented here demonstrate that the
performance of ADXBLADDER is not affected by benign
conditions, such as urinary tract infections or the presence
of haematuria. It has shown a high level of diagnostic
sensitivity, in particular for stage pT1 and above (sensitivityon-invasive Test Enabling Bladder Cancer Detection in Urine
ulticentre Performance Evaluation of ADXBLADDER. Eur Urol
Fig. 2 – (A) Workflow of 593 eligible patients with a documented record of whether haematuria was visible or nonvisible. (B) Performance comparison
of ADXBLADDER between patients presenting with either visible or nonvisible haematuria. (C) Comparison of ROC curves of age, gender, and type of
haematuria. CI = confidence interval; ROC = receiver operator characteristic.
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urine cytology demonstrates that ADXBLADDER has the
potential to replace cytology as an adjunctive test in bladder
cancer diagnosis; however, the authors acknowledge that
the number of available cytology comparisons was smallPlease cite this article in press as: Dudderidge T, et al. A Novel, n
Sediment of Patients Presenting with Haematuria—A Prospective M
Oncol (2019), https://doi.org/10.1016/j.euo.2019.06.006and this study population should be extended to demon-
strate a statistically significant increase in the performance
of ADXBLADDER when compared with cytology.
The ADXBLADDER non-invasive urine test is an easy-to-
perform ELISA test, compatible with general laboratoryon-invasive Test Enabling Bladder Cancer Detection in Urine
ulticentre Performance Evaluation of ADXBLADDER. Eur Urol
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provide results within 3 h, without the need for a
pathologist, making it a potential low-cost alternative to
cytology. Owing to the prospective nature of this study and
the failure to collect cytology data for all patients, a full cost
analysis could not be carried out on the potential cost
savings. However, further studies, including cost-effective-
ness analyses to include cytology as a comparator, are
currently underway to define the optimal place where
ADXBLADDER could be utilised to strengthen the current
diagnostic pathway. Additionally, we postulate that
ADXBLADDER also has a role in the surveillance of patients
with known, non-muscle-invasive bladder cancer, with a
negative test perhaps allowing a greater time period
between check cystoscopies. This hypothesis requires a
specific study to confirm or deny it; such a study is currently
recruiting.
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